Olivia Friett

4 days ago | med-techinsights.com | Olivia Friett

A new point of care test for pre-eclampsia is set to revolutionise testing for suspected pre-eclampsia in maternity units across the UK, aiding early detection and prognosis in pregnant women between 20-37 weeks of gestation. Placental growth factor (PLGF) was first recommended by NICE in 2016 for use in pregnant women, but since this time its use has been confined mainly to hospital laboratories.

4 days ago | med-techinsights.com | Olivia Friett

Inne, a healthtech startup empowering women to understand their reproductive health, has ‘broken through decades of stagnation’ in women’s health and become what it says is the first new tech-enabled contraception to receive certification in the UK and Europe with its Minilab saliva test device. Following a year-long clinical study in which 300 women tracked over 1,500 cycles, inne received certification as a new modern, technology-enabled contraception method.

Feb 26, 2025 | med-techinsights.com | Olivia Friett

FemTech, the sector focused on technology-driven women’s health solutions, is experiencing rapid growth. However, unique challenges exist in research, development, and innovation within this space. Sarah Bandy, assistant research and development manager and Kanika Mishra-Pathak, tax director at MHA Accountants and Advisors explore these challenges, and examine strategies for successful FemTech development.

Oct 11, 2024 | med-technews.com | Olivia Friett

The Women's Health Impact Network (WHIN) is a free digital platform where ideas around women's health transform into impactful actions. Every day, we hear stories of women not being listened to, being misdiagnosed, or struggling to access essential healthcare—for themselves and their children. It’s happening not just here in the UK but globally, and it often feels like women’s health rights are still being overlooked. That’s where WHIN comes in.

Oct 1, 2024 | med-technews.com | Olivia Friett

University of Iowa Health Care and Naitive Technologies have announced a joint project to evaluate the diagnostic accuracy of OsteoSight, an FDA-designated medical device designed to identify people at risk of low bone mineral density (BMD) using X-rays taken for other reasons. OsteoSight aims to enhance the early detection of osteoporosis, a condition affecting millions globally, and enable more timely interventions.